Compare SNBR & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNBR | INAB |
|---|---|---|
| Founded | 1987 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.9M | 10.6M |
| IPO Year | 1998 | 2021 |
| Metric | SNBR | INAB |
|---|---|---|
| Price | $8.57 | $1.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $8.00 | ★ $108.00 |
| AVG Volume (30 Days) | ★ 891.0K | 52.2K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,440,882,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.49 | $1.53 |
| 52 Week High | $20.73 | $12.53 |
| Indicator | SNBR | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 72.83 | 34.24 |
| Support Level | $7.75 | $1.73 |
| Resistance Level | $8.65 | $1.87 |
| Average True Range (ATR) | 0.75 | 0.13 |
| MACD | 0.32 | -0.02 |
| Stochastic Oscillator | 97.76 | 8.30 |
Sleep Number Corp. is a wellness technology company engaged in the design, manufacturing, marketing and distribution of sleep solutions. The Company generates revenue by marketing and selling its smart beds directly to new and existing customers through its vertically integrated, exclusive, direct-to-consumer retail touch points including Stores, Online, Phone, and Chat (Total Retail). The products offered by the company are Mattresses, Bedding, Pillows and Furniture.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.